Drugs / BMS-963272
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04766476 | Feb → Aug 2021 | NAFLD1 | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04124003 | Oct 2019 → Jan 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04116632 | Sep 2019 → Feb 2020 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT02327273 | Oct 2014 → May 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-963272 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04766476 ↗ |
| Modality | Small molecule | — CHEMBL3912712 ↗ |
| Route | Oral | “following single and multiple oral doses of BMS-963272 in healthy subjects” NCT02327273 ↗ |